pubmed-article:11356715 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11356715 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
pubmed-article:11356715 | lifeskim:mentions | umls-concept:C0037657 | lld:lifeskim |
pubmed-article:11356715 | lifeskim:mentions | umls-concept:C0123258 | lld:lifeskim |
pubmed-article:11356715 | lifeskim:mentions | umls-concept:C0678812 | lld:lifeskim |
pubmed-article:11356715 | lifeskim:mentions | umls-concept:C0699812 | lld:lifeskim |
pubmed-article:11356715 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
pubmed-article:11356715 | lifeskim:mentions | umls-concept:C0005508 | lld:lifeskim |
pubmed-article:11356715 | lifeskim:mentions | umls-concept:C0549193 | lld:lifeskim |
pubmed-article:11356715 | lifeskim:mentions | umls-concept:C0441712 | lld:lifeskim |
pubmed-article:11356715 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:11356715 | pubmed:dateCreated | 2001-5-17 | lld:pubmed |
pubmed-article:11356715 | pubmed:abstractText | Insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) is a potent inhibitor of IGF actions in vitro. However, we found that systemic administration of IGFBP-4 at pharmacological doses caused a significant increase in bone formation parameters in mice by a mechanism that may involve increased IGF bioavailability via proteolysis of IGFBP-4. To evaluate the hypothesis that proteolysis of IGFBP-4 is essential for the stimulatory effects of systemically administered IGFBP-4, we produced wild-type, protease-resistant, and IGFBP-4 proteolytic fragments and evaluated their effects using biochemical markers. Protease-resistant IGFBP-4 was more potent than wild-type IGFBP-4 in inhibiting IGF-I-induced mouse osteoblast cell proliferation in vitro and in inhibiting IGF-I-induced increase in alkaline phosphatase (ALP) activity in bone extract after local administration in vivo. Systemic administration of wild-type IGFBP-4, but not protease-resistant IGFBP-4, increased serum osteocalcin, serum ALP, and ALP in skeletal extracts in a dose-dependent manner, with a maximal effect of 40% (P < 0.05) at 1.25 nmol/mouse. Systemic administration of wild-type, but not protease-resistant, IGFBP-4 increased free IGF-I levels in serum in normal mice. IGF-I, but not wild-type IGFBP-4, increased bone formation parameters in IGF-I-deficient mice. This study demonstrates that systemic administration of IGFBP-4 increases bone formation parameters in mice by increasing IGF bioavailability in the circulation via an IGFBP-4 protease-dependent mechanism. | lld:pubmed |
pubmed-article:11356715 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11356715 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11356715 | pubmed:language | eng | lld:pubmed |
pubmed-article:11356715 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11356715 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:11356715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11356715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11356715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11356715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11356715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11356715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11356715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11356715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11356715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11356715 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11356715 | pubmed:month | Jun | lld:pubmed |
pubmed-article:11356715 | pubmed:issn | 0013-7227 | lld:pubmed |
pubmed-article:11356715 | pubmed:author | pubmed-author:MohanSS | lld:pubmed |
pubmed-article:11356715 | pubmed:author | pubmed-author:BaylinkD JDJ | lld:pubmed |
pubmed-article:11356715 | pubmed:author | pubmed-author:SrivastavaA... | lld:pubmed |
pubmed-article:11356715 | pubmed:author | pubmed-author:RichmanCC | lld:pubmed |
pubmed-article:11356715 | pubmed:author | pubmed-author:MiyakoshiNN | lld:pubmed |
pubmed-article:11356715 | pubmed:author | pubmed-author:QiuSS | lld:pubmed |
pubmed-article:11356715 | pubmed:author | pubmed-author:KasukawaYY | lld:pubmed |
pubmed-article:11356715 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11356715 | pubmed:volume | 142 | lld:pubmed |
pubmed-article:11356715 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11356715 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11356715 | pubmed:pagination | 2641-8 | lld:pubmed |
pubmed-article:11356715 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:meshHeading | pubmed-meshheading:11356715... | lld:pubmed |
pubmed-article:11356715 | pubmed:year | 2001 | lld:pubmed |
pubmed-article:11356715 | pubmed:articleTitle | Systemic administration of insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism. | lld:pubmed |
pubmed-article:11356715 | pubmed:affiliation | Musculoskeletal Disease Center, J. L. Pettis Veterans Administration Medical Center, Loma Linda, California 92357, USA. | lld:pubmed |
pubmed-article:11356715 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:11356715 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
pubmed-article:11356715 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11356715 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11356715 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11356715 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11356715 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11356715 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11356715 | lld:pubmed |